Upendra K Jain1,
Richa K Bhatia1,
Akkinepally R Rao2 
,
Ranjit Singh3,
Ajit K Saxena4,
Irum Sehar4
For correspondence:- Akkinepally Rao Email: raghumed@gmail.com Tel:+918702446259
Received: 18 November 2012 Accepted: 8 November 2013 Published: 25 January 2014
Citation: Jain UK, Bhatia RK, Rao AR, Singh R, Saxena AK, Sehar I. Design and Development of Halogenated Chalcone Derivatives as Potential Anticancer Agents. Trop J Pharm Res 2014; 13(1):73-80 doi: 10.4314/tjpr.v13i1.11
© 2014 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To design and develop halogenated chalcone derivatives and evaluate them as anticancer agents using different cancer cell lines.
Methods: Based on in silico design and docking on known target, crystal structure of the complex of interleukin-1beta converting enzyme (ICE) with a peptide based inhibitor, (3S )-N-Methanesulfonyl-3-({1-[N-(2-naphtoyl)-l-valyl]-l-prolyl}amino)-4-oxobutanamide (1BMQ), novel halogenated chalcone derivatives were designed (7a-h) employing LigandFit module of Accelrys (Discovery Studio, 2.1 version). Standard protocols for ligand and protein preparation were employed and their binding orientation validated using (3S)-N-Methanesulfonyl-3-({1-[N-(2-naphtoyl)-l-valyl]-l-prolyl}amino)-4-oxobutanamide (MNO 601), a caspase inhibitor as reference standard. Energy minimized conformers with best dock scores were considered for the identification of interacting amino acid residues with ligands. Selected derivatives were synthesized and analyzed by melting point, 1H NMR, IR and mass spectroscopy. Their evaluation for anticancer activity was carried out using adriamycin, paclitaxel and 5-fluorouracil as reference standards on prostrate (PC-3), colon (COLO-205), ovary (OVCAR-5), liver (HEP-2) and neuroblastoma (IMR-32) cancer cell lines, and % growth inhibition and half maximal inhibitory concentration (IC50) values were calculated.
Results: Among synthesized compounds, 7b showed the most promising cytotoxic activity with an IC50 of 49.9 µM on colon cancer cell lines (Colo-205), followed by 7d with an IC50 of 66.6 µM against ovarian cancer cell lines (OVCAR-5).
Conclusion: We report the successful synthesis, spectral characterization and in vitro anticancer evaluation of a series of novel halogenated chalcone derivatives against a number of human cancer cell lines. The findings indicate the emergence of new anticancer compounds.
Archives
News Updates
Fulltext in PDF